Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy through its brain-responsive RNS System. The NeuroPace news feed on Stock Titan highlights company announcements that relate to financial performance, clinical evidence, regulatory milestones, reimbursement developments, and technology progress in neuromodulation and AI-enabled epilepsy care.
Investors and clinicians following NPCE can find updates on quarterly and annual financial results, revenue trends driven by RNS System sales, and guidance for future periods. NeuroPace frequently reports on gross margin performance, operating expenses, and strategic decisions such as focusing organizational efforts on its differentiated RNS System and treating certain distribution activities as discontinued operations for reporting purposes.
The news flow also includes clinical and regulatory developments, such as preliminary data from the NAUTILUS trial in antiseizure-medication resistant idiopathic generalized epilepsy (IGE), which has shown substantial median reductions in generalized tonic-clonic seizures and a favorable safety profile. NeuroPace provides updates on its Premarket Approval Supplement submissions to the U.S. Food and Drug Administration (FDA) for expanded RNS System indications, Breakthrough Device Designation for IGE, and progress in pediatric and AI software programs.
Another important category of news involves reimbursement and policy. NeuroPace has announced favorable Medicare Physician Fee Schedule and Outpatient Prospective Payment System decisions that increase reimbursement for RNS System implantation and replacement procedures and maintain stable inpatient classifications, developments the company describes as supportive of neurosurgeon adoption and patient access.
In addition, the NPCE news stream features participation in major medical and investor conferences, including the American Epilepsy Society Annual Meeting and large healthcare investment conferences, where NeuroPace presents Post-Approval Study data, NAUTILUS results, and demonstrations of NeuroPace AI and SeizureID tools. Users who want to monitor how clinical evidence, reimbursement, and AI-enabled tools evolve around the RNS System can review and revisit this news page for the latest company-issued information and event updates.
NeuroPace (NASDAQ: NPCE) reported Q3 2025 revenue of $27.4M, up 30% year‑over‑year, with RNS System revenue of $22.6M (+31%). Gross margin was 77.4%. Net loss was $3.5M and loss from operations was $2.6M. Cash, cash equivalents and short‑term investments were $60.0M and long‑term borrowings were $58.7M as of Sept 30, 2025.
The company increased full‑year 2025 revenue guidance to $97M–$98M (growth 21%–23%) and raised gross margin guidance to 76%–77%. Operational updates include submitting Seizure ID to the FDA, a completed FDA pre‑submission for the NAUTILUS IGE study, and plans to submit a PMA supplement for IGE by year‑end 2025.
NeuroPace (Nasdaq: NPCE) will report third quarter 2025 financial results after market close on November 4, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET the same day.
Investors can listen via a live webcast at the events page or join by phone at +1 (800) 715-9871 using Conference ID 8467256. The webcast will be archived on the company investor relations site and will be available for replay for at least 90 days.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its participation in two upcoming healthcare conferences in September 2025. The management team will attend the Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one investor meetings.
Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4 at 9:45am ET. The fireside chat will be available via live webcast, with a replay accessible through NeuroPace's investor website.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, reported strong Q2 2025 financial results. The company achieved record quarterly revenue of $23.5 million, representing a 22% year-over-year growth. Gross margin improved to 77.1%, up from 73.4% in Q2 2024.
The company increased its 2025 revenue guidance to $94-98 million (18-23% growth) and raised gross margin guidance to 75-76%. Key operational highlights include preliminary data from the NAUTILUS study for IGE therapy, showing a 79% median GTC seizure reduction at 12 months. NeuroPace also secured a new $75 million credit facility with MidCap Financial and maintained favorable CMS reimbursement status for RNS procedures.
NeuroPace (Nasdaq: NPCE) announced that the Centers for Medicare & Medicaid Services (CMS) has maintained the current Medicare Severity Diagnosis Related Group (MS-DRG) assignment for RNS® System procedures under MS-DRG 023 for FY 2026. This decision comes after CMS initially proposed reassigning epilepsy with neurostimulator cases to MS-DRG 020-022.
CEO Joel Becker welcomed the decision, highlighting its importance for hospitals providing RNS System treatment to Medicare beneficiaries. The company will continue collaborating with CMS on MS-DRG improvements and reimbursement policies to ensure broader access to their epilepsy treatment technology.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has announced a strategic CFO transition. Patrick F. Williams has been appointed as the new Chief Financial Officer effective June 20, 2025, replacing Rebecca Kuhn, who will serve in an advisory role for 12 months.
Williams brings over 25 years of financial and operational management experience in public medical device companies, having previously served as CFO at STAAR Surgical, Sientra, and ZELTIQ. The company's RNS System targets a significant market opportunity of approximately 1.2 million U.S. patients living with drug-resistant epilepsy.